Company intelligence / Profile preview
CoDa Therapeutics
San Diego, California, United Statescodathx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CoDa Therapeutics’ lead product candidate Nexagon® has shown dramatic improvement in wound healing and tissue repair across multiple preclinical models. Compassionate use cases have demonstrated complete recovery from severe injuries unresponsive to standard therapies. The company’s approach—modulating gap junctions to control cell-to-cell communication—represents a novel paradigm for wound care by improving healing while reducing inflammation and scarring. Clinical programs are ongoing to demonstrate safety and efficacy[1][3].
- Therapeutic areas
- DermatologyOphthalmologyNeurology
- Modalities
- Small moleculeGap junction modulator
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Initial clinical research with University of AucklandInitial clinical research with University College London
Beyond the preview
Go deeper on CoDa Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoDa Therapeutics.